Serum levels of YKL-40 are increased in patients with psoriasis: a meta-analysis

References

• Zheng Y, Luo S, Wang G, et al. Downregulation of tazarotene induced gene-2 (TIG2) in skin squamous cell carcinoma. Eur J Dermatol. 2008 Nov;18(6):638–641. PubMed PMID: 18955196; eng.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Iizuka H. Psoriasis and metabolic syndrome. J Dermatol. 2012 Mar;39(3):212–218. PubMed PMID: 22035413; eng.
   PubMed Web of Science ®Google Scholar
• Di Minno MND, Iervolino S, Peluso R, et al. Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis. Clin Rheumatol. 2011 Jul;30(7):915–919. PubMed PMID: 21327686; eng.
   PubMed Web of Science ®Google Scholar
• Di Minno MND, Peluso R, Iervolino S, et al. Obesity and the prediction of the minimal disease activity. A prospective study in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2013 Jan;65(1):141–147. PubMed PMID: 22514189; eng.
   PubMed Web of Science ®Google Scholar
• Zhu KJ, Shi G, Zhang C, et al. Adiponectin levels in patients with psoriasis: a meta-analysis. J Dermatol. 2013 Jun;40(6):438–442. PubMed PMID: 23731474; eng.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009 Oct;51(4):758–764. PubMed PMID: 19560226; eng.
   PubMed Web of Science ®Google Scholar
• Boehncke S, Thaci D, Beschmann H, et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol. 2007 Dec;157(6):1249–1251. PubMed PMID: 17916217; eng.
   PubMed Web of Science ®Google Scholar
• Russolillo A, Iervolino S, Peluso R, et al. Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford). 2013 Jan;52(1):62–67. PubMed PMID: 22989426; eng.
   PubMed Web of Science ®Google Scholar
• Alpsoy S, Akyuz A, Erfan G, et al. Atherosclerosis, some serum inflammatory markers in psoriasis. G Ital Dermatol Venereol. 2014 Apr;149(2):167–175. PubMed PMID: 24819636; eng.
   PubMed Web of Science ®Google Scholar
• Pouyafar A, Heydarabad MZ, Mahboob S, et al. Angiogenic potential of YKL-40 in the dynamics of tumor niche. Biomed Pharmacother. 2018 Apr;100(5):478–485. PubMed PMID: 29477911; eng.
   PubMedGoogle Scholar
• Ngernyuang N, Shao R, Suwannarurk K, et al. Chitinase 3 like 1 (CHI3L1) promotes vasculogenic mimicry formation in cervical cancer. Pathology. 2018 Apr;50(3):293–297. PubMed PMID: 29452694; eng.
   PubMed Web of Science ®Google Scholar
• Salomon J, Piotrowska A, Matusiak L, et al. Chitinase-3-like Protein 1 (YKL-40) Expression in Squamous Cell Skin Cancer. Anticancer Res. 2018 Aug;38(8):4753–4758. PubMed PMID: 30061245; eng.
   PubMed Web of Science ®Google Scholar
• Brahe CH, Dehlendorff C, Ostergaard M, et al. Circulating serum interleukin-6, serum chitinase-3-like protein-1, and plasma vascular endothelial growth factor are not predictive for remission and radiographic progression in patients with early rheumatoid arthritis: post-hoc explorative and validation studies based on the CIMESTRA and OPERA trials. Scand J Rheumatol. 2018 Jul;47(4):259–269. PubMed PMID: 29336711; eng.
   PubMed Web of Science ®Google Scholar
• Tong X, Wang D, Liu S, et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis. 2018 Jan;13(9):409–418. PubMed PMID: 29430175; eng.
   PubMedGoogle Scholar
• Imai Y, Aochi S, Iwatsuki K, et al. YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis. J Dermatol. 2013 Apr;40(4):294–296. PubMed PMID: 23397985; eng.
   PubMed Web of Science ®Google Scholar
• Guan J, Liu Z, Li F, et al. Increased synovial fluid YKL-40 levels are linked with symptomatic severity in knee osteoarthritis patients. Clin Lab. 2015;61(8):991–997. PubMed PMID: 26427144; eng.
   PubMed Web of Science ®Google Scholar
• Umapathy D, Dornadula S, Krishnamoorthy E, et al. YKL-40: a biomarker for early nephropathy in type 2 diabetic patients and its association with inflammatory cytokines. Immunobiology. 2018 Nov;223(11):718–727. PubMed PMID: 30077474; eng.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009 Oct;62(10):1006–1012. PubMed PMID: 19631508; eng.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 Sep 6;327(7414):557–560. PubMed PMID: 12958120; eng.
   PubMed Web of Science ®Google Scholar
• Bernardi D, Podswiadek M, Zaninotto M, et al. YKL-40 as a marker of joint involvement in inflammatory bowel disease. Clin Chem. 2003 Oct;49(10):1685–1688. PubMed PMID: 14500601; eng.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Hetland ML, Sorensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFalpha inhibitors. Clin Rheumatol. 2010 Nov;29(11):1301–1309. PubMed PMID: 20640910; eng.
   PubMed Web of Science ®Google Scholar
• Imai Y, Tsuda T, Aochi S, et al. YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis. J Dermatol Sci. 2011 Oct;64(1):75–77. PubMed PMID: 21782391; eng.
   PubMed Web of Science ®Google Scholar
• Jensen P, Wiell C, Milting K, et al. Plasma YKL-40: a potential biomarker for psoriatic arthritis?. J Eur Acad Dermatol Venereol. 2013 Jul;27(7):815–819. PubMed PMID: 22621388; eng.
   PubMed Web of Science ®Google Scholar
• Erfan G, Guzel S, Alpsoy S, et al. Serum YKL-40: a potential biomarker for psoriasis or endothelial dysfunction in psoriasis? Mol Cell Biochem. 2015 Feb;400(1–2):207–212. PubMed PMID: 25421412; eng.
   PubMed Web of Science ®Google Scholar
• Ataseven A, Kesli R. Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40. G Ital Dermatol Venereol. 2016 Jun;151(3):244–250. PubMed PMID: 25279492; eng.
   PubMed Web of Science ®Google Scholar
• Salomon J, Matusiak L, Nowicka-Suszko D, et al. Chitinase-3-like protein 1 (YKL-40) is a new biomarker of inflammation in psoriasis. Mediators Inflamm. 2017;2017:9538451. PubMed PMID: 28932021; eng.
   PubMedGoogle Scholar
• Abu El-Hamd M, Adam El Taieb M, Mahmoud AA, et al. Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy. J Dermatolog Treat. 2018 Nov 28;(1):1–4. PubMed PMID: 30482111; eng.
   PubMedGoogle Scholar
• Baran A, Mysliwiec H, Szterling-Jaworowska M, et al. Serum YKL-40 as a potential biomarker of inflammation in psoriasis. J Dermatolog Treat. 2018 Feb;29(1):19–23. PubMed PMID: 28498006; eng.
   PubMed Web of Science ®Google Scholar
• Salomon J, Matusiak L, Nowicka-Suszko D, et al. Chitinase-3-like protein 1 (YKL-40) is a biomarker of severity of joint involvement in psoriatic arthritis. Postepy Dermatol Alergol. 2018 Oct;35(5):485–489. PubMed PMID: 30429706; eng.
   PubMed Web of Science ®Google Scholar
• Eder L, Jayakar J, Pollock R, et al. Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. Ann Rheum Dis. 2013 Dec;72(12):1956–1961. PubMed PMID: 23243196; eng.
   PubMed Web of Science ®Google Scholar
• Kondelkova K, Borska L, Andrys C, et al. Selected inflammatory and metabolic markers in psoriatic patients treated with goeckerman therapy. Mediators Inflamm. 2015;2015:979526. PubMed PMID: 26166954; eng.
   PubMedGoogle Scholar
• Krasowska D, Adamczyk M. Anti-endothelial cell antibodies do not correlate with disease activity in systemic sclerosis. Postepy Dermatol Alergol. 2018 Apr;35(2):185–191. PubMed PMID: 29760620; eng.
   PubMed Web of Science ®Google Scholar
• Gulliver WP, Young HM, Bachelez H, et al. Psoriasis patients treated with biologics and methotrexate have a reduced rate of myocardial infarction: a collaborative analysis using international cohorts. J Cutan Med Surg. 2016 Nov;20(6):550–554. PubMed PMID: 27402717; eng.
   PubMed Web of Science ®Google Scholar
• Korotaeva TV, Novikova DS, Loginova EY. Cardiovascular risk in patients with psoriatic arthritis. Ter Arkh. 2016 Oct;88(5):102–106. PubMed PMID: 27458624; eng.
   PubMed Web of Science ®Google Scholar
• Granata M, Skarmoutsou E, Trovato C, et al. Obesity, type 1 diabetes, and psoriasis: an Autoimmune Triple Flip. Pathobiology. 2017;84(2):71–79. PubMed PMID: 27639922; eng.
   PubMed Web of Science ®Google Scholar
• Hu SC, Lan CE. Psoriasis and cardiovascular comorbidities: focusing on severe vascular events, cardiovascular risk factors and implications for treatment. Int J Mol Sci. 2017 Oct 21;18(10):453–457. PubMed PMID: 29065479; eng.
   Web of Science ®Google Scholar
• Stougaard J, Lomholt S, Ommen P, et al. The antifibrotic drug pirfenidone inhibits spondyloarthritis fibroblast-like synoviocytes and osteoblasts in vitro. BMC Rheumatol. 2018 Nov;19(2):33. PubMed PMID: 30886983; eng.
   Google Scholar
• Furukawa T, Matsui K, Kitano M, et al. Relationship between YKL-40 and pulmonary arterial hypertension in systemic sclerosis. Mod Rheumatol. 2019 May;29(3):476–483. PubMed PMID: 29788800; eng.
   PubMed Web of Science ®Google Scholar
• Salomon J, Piotrowska A, Matusiak L, et al. Chitinase-3-like protein 1 (YKL-40) is expressed in lesional skin in hidradenitis suppurativa. In Vivo. 2019 Jan-Feb;33(1):141–143. PubMed PMID: 30587614; eng.
   PubMed Web of Science ®Google Scholar
• Temel Yuksel I, Aslan Cetin B, Koroglu N, et al. Inflammatory marker YKL-40 levels in intrahepatic cholestasis of pregnancy. Gynecol Endocrinol. 2019 Jul;35(7):635–637. PubMed PMID: 30688121; eng.
   PubMed Web of Science ®Google Scholar